Searching for new detoxification strategies

September 16, 2001

Alcohol withdrawal syndrome (AWS) can range from no symptoms to agitation and intense anxiety to tremors, seizures, delusions, fatal increases in body temperature, and cardiovascular collapse. Benzodiazepines are to alcohol what methadone is to heroin; that is, they provide an alcohol-like effect, relieving AWS symptoms by substituting for the alcohol that is no longer present in the system. However, benzodiazepines are similar enough to alcohol to have significant potential for intoxication, abuse and even dependence. A study in the September issue of Alcoholism: Clinical & Experimental Research examines the viability of an anticonvulsant agent called divalproex sodium as an alternative to benzodiazepines for treating AWS.

"Alcohol, benzodiazepines, and divalproex sodium all enhance gamma-aminobutyric acid (GABA) neurotransmission, one of the brain systems that becomes unbalanced during alcohol withdrawal," said Joseph P. Reoux, a psychiatrist with the Veterans Affairs Puget Sound Health Care System and lead author of the study. "More specifically, certain anticonvulsants appear to prevent the nervous system hyperexcitability that develops during alcohol withdrawal. Although an anticonvulsant like divalproex sodium enhances the same brain inhibitory system that alcohol and benzodiazepines do, it does not have the euphoria, abuse potential, or as high of a risk for cognition impairment that can occur with benzodiazepines. It also has anti-kindling properties, and tends to be better tolerated than carbamazepine (another anticonvulsant that can be used to treat alcohol withdrawal)."

"Kindling" occurs when the nervous system develops increased sensitivity to a stimulus such as withdrawal from alcohol. (Enhanced withdrawal responses are referred to as a "kindling effect" because of their similarity to the kindling of brain seizures.) When a nerve cell is repeatedly exposed to a stimulus that is initially too small to cause full nerve excitement, it can become more sensitive, or kindled, to the stimulus and begin to react at lower thresholds. This sensitivity persists over time and can become stronger with continued exposure to the stimulus. The concept of neuronal kindling is used to understand what clinicians may see during alcohol withdrawal: symptoms tend to become worse over time in people who repeatedly expose their brains to withdrawal from alcohol. Certainly kindling can complicate addiction by contributing to an individual's unwillingness to forego alcohol, even when its ingestion is no longer a source of pleasure.

Researchers gave a primarily male inpatient population either 500 mg of the divalproex sodium formulation of divalproex sodium (also called valproate) or a placebo three times a day. Because the study participants were already experiencing withdrawal symptoms at a level that is normally medicated, they were also given a baseline dose of oxazepam (a benzodiazepine sedative) to ease their discomfort, as well as additional oxazepam if and when the severity of their withdrawal symptoms warranted it. During the seven-day study period, divalproex sodium reduced the amount of the oxazepam needed to adequately treat alcohol withdrawal. Adding divalproex sodium to the treatment regimen also appeared to stop the withdrawal symptoms from becoming worse when compared to giving oxazepam alone.

"The findings certainly support the idea that valproate is a viable treatment option for AWS," said Reoux, "although it would be more correct to say that this study showed that using divalproex sodium significantly reduces the amount of benzodiazepine needed for the treatment of AWS. One of the more important aspects of this study is that it was scientifically rigorous. Previous studies of valproate for AWS were not randomized double-blind placebo controlled trials, so this study provides the strongest evidence to date supporting the use of valproate in the treatment of alcohol withdrawal." Reoux added that larger studies in broader patient populations, including women and outpatients, would likely be necessary before valproate is accepted as a first-line treatment for AWS in the United States.

The anticonvulsant valproate has been available in Europe for treating AWS since the 1960s, but has only been marketed in the U.S. since 1978. In the U.S., benzodiazepines comprise the drug regimen of choice, despite their potential for abuse.

"Many medications are used differently in other places," explained Richard K. Ries, a professor of psychiatry and addictions at the University of Washington. "Much of this has to do with what clinicians are used to doing. Sometimes this also has to do with pharmaceutical company marketing. Or sometimes it's due to what the federal Food and Drug Administration allows. For example, many meds are available in Europe well before they are available here, which has been true of many of the anticonvulsants."

Ries is intrigued by the study's findings because of the potential for valproate to become a new detoxification strategy.

"AWS is an immense problem which affects patients in medical, surgical, and psychiatric settings as well as in addiction treatment populations," he said. "Yet there is a paucity of research documenting new and better ways to deal with it. This pilot study makes a good attempt to address this and highlights the need for more research.
-end-
Co-authors of the Alcoholism: Clinical & Experimental Research paper included: Andrew J. Saxon, John Baer, and Kevin Sloan of Veterans Affairs Puget Sound Health Care System, and the Department of Psychiatry at the University of Washington School of Medicine; and Carol A. Malte of Veterans Affairs Puget Sound Health Care System. The study was funded by the Alcohol and Drug Abuse Institute at the University of Washington.

Alcoholism: Clinical & Experimental Research

Related Alcohol Articles from Brightsurf:

Alcohol use changed right after COVID-19 lockdown
One in four adults reported a change in alcohol use almost immediately after stay-at-home orders were issued: 14% reported drinking more alcohol and reported higher levels of stress and anxiety than those who did not drink and those whose use stayed the same.

Changes in hospitalizations for alcohol use disorder in US
Changes over nearly two decades in the rate of hospitalizations and in-hospital deaths from alcohol use disorder in the US were examined in this study.

Associations of alcohol consumption, alcohol-induced passing out with risk of dementia
The risk of future dementia associated with overall alcohol consumption and alcohol-induced loss of consciousness in a population of current drinkers was examined in this observational study with more than 131,000 adults.

New alcohol genes uncovered
Do you have what is known as problematic alcohol use?

Does estrogen influence alcohol use disorder?
A new study from researchers at the University of Illinois at Chicago shows that high estrogen levels may make alcohol more rewarding to female mice.

Sobering new data on drinking and driving: 15% of US alcohol-related motor vehicle fatalities involve alcohol under the legal limit
A new study in the American Journal of Preventive Medicine, published by Elsevier, found that motor vehicle crashes involving drivers with blood alcohol concentrations (BACs) below the legal limit of 0.08 percent accounted for 15% of alcohol-involved crash deaths in the United States.

Alcohol-induced deaths in US
National vital statistics data from 2000 to 2016 were used to examine how rates of alcohol-induced deaths (defined as those deaths due to alcohol consumption that could be avoided if alcohol weren't involved) have changed in the US and to compare the results by demographic groups including sex, race/ethnicity, age, socioeconomic status and geographic location.

Cuts in alcohol duty linked to 2000 more alcohol-related deaths in England
Government cuts to alcohol taxes have had dramatic consequences for public health, including nearly 2000 more alcohol-related deaths in England since 2012, according to new research from the University of Sheffield's School of Health and Related Research (ScHARR).

Integrated stepped alcohol treatment for people in HIV care improves both HIV & alcohol outcomes
Increasing the intensity of treatment for alcohol use disorder (AUD) over time improves alcohol-related outcomes among people with HIV, according to new clinical research supported by the National Institutes of Health.

The Lancet:Targets to reduce harmful alcohol use are likely to be missed as global alcohol intake increases
Increasing rates of alcohol use suggest that the world is not on track to achieve targets against harmful alcohol use, according to a study of 189 countries' alcohol intake between 1990-2017 and estimated intake up to 2030, published in The Lancet.

Read More: Alcohol News and Alcohol Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.